| Followers | 2543 |
| Posts | 250731 |
| Boards Moderated | 34 |
| Alias Born | 05/06/2014 |
Wednesday, February 07, 2018 12:34:33 AM
$DFFN Breaking News DFFN
“We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”
http://investors.diffusionpharma.com/file/Index?KeyFile=391934667
“We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”
http://investors.diffusionpharma.com/file/Index?KeyFile=391934667
investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
